BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36192179)

  • 21. Features of Patients With Nonfluent/Agrammatic Primary Progressive Aphasia With Underlying Progressive Supranuclear Palsy Pathology or Corticobasal Degeneration.
    Santos-Santos MA; Mandelli ML; Binney RJ; Ogar J; Wilson SM; Henry ML; Hubbard HI; Meese M; Attygalle S; Rosenberg L; Pakvasa M; Trojanowski JQ; Grinberg LT; Rosen H; Boxer AL; Miller BL; Seeley WW; Gorno-Tempini ML
    JAMA Neurol; 2016 Jun; 73(6):733-42. PubMed ID: 27111692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Co-morbidity of progressive supranuclear palsy and amyotrophic lateral sclerosis: a clinical-pathological case report.
    Fujita K; Matsubara T; Miyamoto R; Sumikura H; Takeuchi T; Maruyama Saladini K; Kawarai T; Nodera H; Udaka F; Kume K; Morino H; Kawakami H; Hasegawa M; Kaji R; Murayama S; Izumi Y
    BMC Neurol; 2019 Jul; 19(1):168. PubMed ID: 31319800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pallidonigroluysian atrophy associated with p.A152T variant in MAPT.
    Graff-Radford J; Whitwell JL; Dickson DW; Josephs KA
    Parkinsonism Relat Disord; 2013 Sep; 19(9):838-41. PubMed ID: 23692670
    [No Abstract]   [Full Text] [Related]  

  • 24. Genetics of Progressive Supranuclear Palsy: A Review.
    Wen Y; Zhou Y; Jiao B; Shen L
    J Parkinsons Dis; 2021; 11(1):93-105. PubMed ID: 33104043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration.
    Pittman AM; Myers AJ; Abou-Sleiman P; Fung HC; Kaleem M; Marlowe L; Duckworth J; Leung D; Williams D; Kilford L; Thomas N; Morris CM; Dickson D; Wood NW; Hardy J; Lees AJ; de Silva R
    J Med Genet; 2005 Nov; 42(11):837-46. PubMed ID: 15792962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progressive supranuclear palsy: pathology and genetics.
    Dickson DW; Rademakers R; Hutton ML
    Brain Pathol; 2007 Jan; 17(1):74-82. PubMed ID: 17493041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Progressive supranuclear palsy: what's new?].
    Levy R
    Geriatr Psychol Neuropsychiatr Vieil; 2011 Jun; 9(2):191-201. PubMed ID: 21690028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tauopathy with hippocampal 4-repeat tau immunoreactive spherical inclusions: a report of three cases.
    Kovacs GG; Kwong LK; Grossman M; Irwin DJ; Lee EB; Robinson JL; Suh E; Van Deerlin VM; Lee VM; Trojanowski JQ
    Brain Pathol; 2018 Mar; 28(2):274-283. PubMed ID: 28019685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathomechanisms of cognitive impairment in progressive supranuclear palsy.
    Jellinger KA
    J Neural Transm (Vienna); 2023 Apr; 130(4):481-493. PubMed ID: 36862189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In Vivo Assessment of Neuroinflammation in 4-Repeat Tauopathies.
    Palleis C; Sauerbeck J; Beyer L; Harris S; Schmitt J; Morenas-Rodriguez E; Finze A; Nitschmann A; Ruch-Rubinstein F; Eckenweber F; Biechele G; Blume T; Shi Y; Weidinger E; Prix C; Bötzel K; Danek A; Rauchmann BS; Stöcklein S; Lindner S; Unterrainer M; Albert NL; Wetzel C; Rupprecht R; Rominger A; Bartenstein P; Herms J; Perneczky R; Haass C; Levin J; Höglinger GU; Brendel M
    Mov Disord; 2021 Apr; 36(4):883-894. PubMed ID: 33245166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Divergent CSF τ alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy.
    Wagshal D; Sankaranarayanan S; Guss V; Hall T; Berisha F; Lobach I; Karydas A; Voltarelli L; Scherling C; Heuer H; Tartaglia MC; Miller Z; Coppola G; Ahlijanian M; Soares H; Kramer JH; Rabinovici GD; Rosen HJ; Miller BL; Meredith J; Boxer AL
    J Neurol Neurosurg Psychiatry; 2015 Mar; 86(3):244-50. PubMed ID: 24899730
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A follow-up study on brainstem atrophy in progressive supranuclear palsy--when does brain MRI contribute to the differential diagnosis between progressive supranuclear palsy and Parkinson disease?].
    Yamamoto T; Oya Y; Ogawa M; Ogata K; Kawai M
    Rinsho Shinkeigaku; 2003 Jul; 43(7):392-7. PubMed ID: 14582364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The MAPT gene is differentially methylated in the progressive supranuclear palsy brain.
    Huin V; Deramecourt V; Caparros-Lefebvre D; Maurage CA; Duyckaerts C; Kovari E; Pasquier F; Buée-Scherrer V; Labreuche J; Behal H; Buée L; Dhaenens CM; Sablonnière B
    Mov Disord; 2016 Dec; 31(12):1883-1890. PubMed ID: 27709663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetics of Progressive Supranuclear Palsy.
    Im SY; Kim YE; Kim YJ
    J Mov Disord; 2015 Sep; 8(3):122-9. PubMed ID: 26413239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy.
    Brendel M; Barthel H; van Eimeren T; Marek K; Beyer L; Song M; Palleis C; Gehmeyr M; Fietzek U; Respondek G; Sauerbeck J; Nitschmann A; Zach C; Hammes J; Barbe MT; Onur O; Jessen F; Saur D; Schroeter ML; Rumpf JJ; Rullmann M; Schildan A; Patt M; Neumaier B; Barret O; Madonia J; Russell DS; Stephens A; Roeber S; Herms J; Bötzel K; Classen J; Bartenstein P; Villemagne V; Levin J; Höglinger GU; Drzezga A; Seibyl J; Sabri O
    JAMA Neurol; 2020 Nov; 77(11):1408-1419. PubMed ID: 33165511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unexpected abundance of pathological tau in progressive supranuclear palsy white matter.
    Zhukareva V; Joyce S; Schuck T; Van Deerlin V; Hurtig H; Albin R; Gilman S; Chin S; Miller B; Trojanowski JQ; Lee VM
    Ann Neurol; 2006 Sep; 60(3):335-45. PubMed ID: 16823854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family.
    Spina S; Farlow MR; Unverzagt FW; Kareken DA; Murrell JR; Fraser G; Epperson F; Crowther RA; Spillantini MG; Goedert M; Ghetti B
    Brain; 2008 Jan; 131(Pt 1):72-89. PubMed ID: 18065436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic variation at the tau locus and clinical syndromes associated with progressive supranuclear palsy.
    Williams DR; Pittman AM; Revesz T; Lees AJ; de Silva R
    Mov Disord; 2007 Apr; 22(6):895-7. PubMed ID: 17274033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Young onset limb spasticity with PSP-like brain and spinal cord NFT-tau pathology.
    Papapetropoulos S; Scaravilli T; Morris H; An SF; Henderson DC; Quinn NP; Scaravilli F; Bhatia KP
    Neurology; 2005 Feb; 64(4):731-3. PubMed ID: 15728304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progressive supranuclear palsy presenting as primary lateral sclerosis but lacking parkinsonism, gaze palsy, aphasia, or dementia.
    Nagao S; Yokota O; Nanba R; Takata H; Haraguchi T; Ishizu H; Ikeda C; Takeda N; Oshima E; Sakane K; Terada S; Ihara Y; Uchitomi Y
    J Neurol Sci; 2012 Dec; 323(1-2):147-53. PubMed ID: 23026537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.